Moximed

Focus: Moximed is a musculoskeletal-focused biotech company headquartered in Fremont, CA, specializing in joint treatment innovations for osteoarthritis. The company operates at an early-stage scale with 8 active job openings and a portfolio of medical device systems targeting knee osteoarthritis.

Musculoskeletal

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Moximed

AI assessmentNot Hiring

No open roles listed right now. Follow Moximed to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Calypso Knee System

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT03838978Calypso Knee System Clinical Study, OUS

N/A

Help build intelligence for Moximed

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focus on high-prevalence musculoskeletal disease (knee osteoarthritis) with large addressable market and unmet clinical need
Diversified pipeline of device-based solutions (Atlas, Calypso, MISHA systems) targeting compartment-specific OA treatment
Balanced hiring across R&D, clinical affairs, regulatory, and commercial functions suggests coordinated advancement toward clinical validation

Watch Out For

Early-stage pipeline with all programs in pre-clinical/non-clinical phase (no traditional drug development milestones) creates execution uncertainty
Minimal public visibility—no publications, recent news, or FDA interactions documented; limited ability to assess scientific credibility or regulatory pathway viability
Small hiring footprint (8 roles) and undisclosed funding/financials raise questions about runway, Series funding stability, and long-term organizational viability

Generated by Claude from Moximed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Survey

Osteoarthritis of the Knee

N/A

Clinical Trials (1)

NCT02934672KineSpring® System Patient Preference Study

N/A

Atlas Knee System

Osteoarthritis (OA) of the Medial Knee Compartment

N/A

Clinical Trials (1)

NCT02663414European Post-Market Study for Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction

N/A